Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics
Published Date : 1st Aug 2018
Authors : Friedlander DF,Trinh QC, Krasnova A, Lipsitz SR, Sun M, Nguyen PL, Kibel AS, Choueire TK, Weissman JS, Menon M, Abdollah F
Procedure Followed : Prostate Cancer Therapy
Institutions : Brigham and Women's Hospital, Division of Urological Surgery, Harvard Medical School, Boston, MA, USA. Brigham and Women's Hospital, Division of Urological Surgery, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: qtrinh@bwh.harvard.edu. Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA.
Abstract : From European Urology Background :
The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races.
Objective :
To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa.
